Estradiol Formulations: Patch, Gel, and Oral Routes

Estradiol Formulations Patch Gel Oral Routes — scientific infographic poster

Not all estrogen is the same, and the route of delivery matters as much as the dose. The same molecule — estradiol — behaves very differently in your body depending on whether it goes through your skin, your mouth, or your bloodstream directly. If you only remember one thing from this page, remember this: transdermal estradiol (patch, gel, or spray) does not raise your clot risk the way oral estrogen does. That single fact has reshaped menopause medicine over the past fifteen years.

This article walks through every common estradiol product on the U.S. market, what a typical starting dose looks like, how doses are adjusted up or down, how switching between routes is done, and why the North American Menopause Society (NAMS, now simply "The Menopause Society") and most modern prescribers now favor the skin over the stomach for most women. We will also cover three formulations you may see mentioned — conjugated equine estrogens, ethinyl estradiol (the estrogen in birth control pills), and compounded "bioidentical" pellets — and explain where each fits, or does not fit, into modern practice.

This is a patient-facing explainer of what the product labels, studies and guidelines say.

🌸 Interactive Visualization Menopause — run the hormones down and set off a hot flash Empty the ovarian follicle pool and watch estradiol swing, then flatten, while follicle-stimulating hormone (FSH) climbs — then trigger a hot flash and see the narrowed thermoneutral zone behind it. Launch →

The Three Estrogens You Might Be Offered
Oral and Transdermal Routes: The First-Pass Liver Effect
The Estradiol Transdermal Patch
Estradiol Gel and Estradiol Spray
Oral Estradiol Tablets (17-Beta-Estradiol)
Starting Doses and Dose Adjustment
Switching Between Routes
Absorption in Overweight and Obese Patients
Cost, Insurance, and Compounded Pellets
What NAMS and Major Societies Say
Key Research Papers
PubMed Topic Searches
Connections
Featured Videos

The Three Estrogens You Might Be Offered

When a prescription label says "estrogen," it can mean one of three very different things. Knowing which one you are getting is the first step.

17-beta-estradiol. This is the exact molecule your ovaries made in your reproductive years — chemically identical, atom for atom. It is the "bioidentical" estrogen. It is U.S. Food and Drug Administration-approved, sold as dozens of generic and brand-name products (oral tablets, patches, gels and sprays), and is the most widely used form today.
Conjugated equine estrogens (CEE). A mixture of about ten different estrogen compounds extracted from the urine of pregnant mares. It contains some estradiol metabolites plus equine-specific estrogens like equilin and equilenin that human bodies do not make and cannot perfectly clear. Conjugated equine estrogens were the dominant menopause drug for fifty years, which is why it appears in almost every major older trial (including the Women's Health Initiative). It still works, but modern prescribing has largely moved on from it.
Ethinyl estradiol. A synthetic estrogen engineered to survive digestion, used in oral contraceptives. It is roughly 100 times more potent per milligram than natural estradiol and has a much stronger effect on liver proteins, clotting factors, and blood pressure. It is not used for menopausal hormone therapy — the risk profile is wrong for an older population. A low-dose birth control pill taken in the late 40s for cycle control contains ethinyl estradiol; most clinicians switch to estradiol-based hormone replacement therapy (HRT) once periods stop.

For the rest of this article, "estradiol" means 17-beta-estradiol, the bioidentical form, unless we say otherwise.

Oral and Transdermal Routes: The First-Pass Liver Effect

When you swallow an estradiol tablet, it is absorbed through your gut wall and carried by the portal vein directly into your liver before it reaches the rest of your body. The liver processes (and largely destroys) most of that first dose — this is the "first-pass effect." To deliver a useful amount of estradiol to your bloodstream, the oral dose has to be high enough that what survives is still meaningful. While the liver is doing all this work on a flood of estrogen, it changes how it makes several proteins:

Clotting factors go up. Factors II, VII, IX, X, and fibrinogen all rise. This is the mechanism behind the increased venous thromboembolism (VTE) risk seen with oral estrogen. The landmark Canonico 2007 ESTHER study showed roughly four times the clot risk with oral estrogen compared to non-users, while transdermal users had no detectable increase over baseline. A 2015 meta-analysis of 15 observational studies (Mohammed and colleagues) found oral estrogen associated with a higher risk of a first VTE than transdermal estrogen (risk ratio 1.63) and possibly of stroke (risk ratio 1.24, from a single case-control study), and rated the evidence as warranting low confidence.
Triglycerides go up. Oral estrogen can push triglycerides 20–40% higher, occasionally enough to matter in women who already have high triglycerides or metabolic syndrome.
Sex hormone binding globulin (SHBG) goes up sharply. SHBG is the protein that binds testosterone in your blood and keeps it inactive. An oral estrogen dose can double or triple SHBG, which drops your free testosterone and can worsen libido, energy, and mood. This is a common reason women feel "off" on oral hormone replacement therapy despite otherwise good symptom control.
C-reactive protein goes up. Oral estrogen raises C-reactive protein (CRP) independent of actual inflammation — another liver-protein quirk.

Estradiol absorbed through the skin skips all of this. It goes straight into your general circulation at low, steady concentrations, reaches the brain, bones, and blood vessels, and does not flood the liver. Clotting factors, triglycerides, and SHBG stay roughly where they were. That is the single biggest reason transdermal is the preferred route for most women today, and the specific reason guidelines prefer it for women with a history of clots, migraine with aura, obesity, high triglycerides, gallbladder disease, or a strong family clot history.

The Estradiol Transdermal Patch

The estradiol patch is a small, clear or flesh-colored adhesive square that slowly releases 17-beta-estradiol through your skin over several days.

Common products and schedules:

Twice-weekly estradiol patches — changed every 3–4 days. The smallest are roughly the size of a nickel or quarter. Doses: 0.025, 0.0375, 0.05, 0.075, 0.1 mg per day.
Once-weekly estradiol patches — changed once weekly. Larger patch. Same dose range.
Very small twice-weekly patches sold in Canada, the UK and Europe, with the same delivery system as the small U.S. twice-weekly patches.
Estradiol/norethindrone acetate patch — a twice-weekly patch combining estradiol with the progestin norethindrone acetate; used in women with a uterus as single-patch delivery of both hormones. Note: this pairs transdermal estradiol with a synthetic progestin rather than micronized progesterone — see the progesterone vs progestins article for the trade-off.

Typical dose range: 0.025 to 0.1 mg per day. Most women land somewhere between 0.05 and 0.075 mg. A 0.025 mg patch is often enough for bone protection and mild symptoms; 0.05 mg is a common "full" starting dose for moderate hot flashes; 0.075 and 0.1 mg are reserved for women who are younger (surgical menopause, premature ovarian insufficiency) or who do not respond to standard doses.

Where it is applied: The label sites are the lower abdomen or upper buttock/hip, on clean, dry, hairless skin — not the breasts. Sites are rotated with each change, because a new patch on the exact spot of the old one causes skin irritation. The waistband area, where clothing rubs, tends to pull patches off. The patch is designed to stay on through bathing, swimming, and exercise. A patch that falls off early is pressed back on or replaced, keeping the same change-day schedule.

Skin reactions are the main downside — redness, itching at the site, occasional rash. Rotating sites usually solves this. A few women cannot tolerate any adhesive and move to gel or spray.

Estradiol Gel and Estradiol Spray

For women who dislike patches or react to the adhesive, transdermal gels and sprays deliver the same estradiol through the skin in a different vehicle.

Estradiol gel in single-use packets — foil packets (0.25, 0.5, 0.75, 1.0, 1.25 mg of estradiol per packet). Applied once daily to a 5-by-7-inch area on one upper thigh. Alternate thighs day to day.
Estradiol gel in a metered pump (0.75 mg) — 0.75 mg estradiol per pump. One or two pumps daily, applied to one arm from wrist to shoulder. Alternate arms.
Estradiol gel in a metered pump (0.52 mg) — 0.52 mg per pump. Applied to the upper arm.
Estradiol spray — a metered spray, 1.53 mg estradiol per spray. One to three sprays on the inner forearm once daily.

Typical dose range: Roughly 0.5 to 1.5 mg of estradiol per day transdermally via gel. Bloodstream levels achieved are comparable to a 0.025–0.075 mg patch.

Application points that matter:

The gel is left to dry completely (a few minutes) before dressing or applying sunscreen.
Hands are washed thoroughly after applying.
Estradiol can pass to other people — especially children, pregnant partners, or pets — who touch the application area before it has dried and been covered with clothing. Small but real transfer cases have been documented.
Showering or swimming is usually left until at least an hour after applying.
Some sunscreens applied directly on the application site increase estradiol absorption unpredictably.

Gels offer slightly more dose flexibility than patches (you can use half a packet, or one pump instead of two), which some women prefer for titration. The main drawbacks are price (see cost section below) and the daily ritual.

Oral Estradiol Tablets (17-Beta-Estradiol)

Oral 17-beta-estradiol is still a legitimate option — it is cheap, simple, and effective for symptom control. It just carries the first-pass liver effects described above.

Oral estradiol tablets (brand and generic) — 0.5, 1.0, and 2.0 mg. Typical doses: 1 mg daily for most women, 2 mg for stronger symptom control, 0.5 mg for low-dose maintenance.
Conjugated estrogens (conjugated equine estrogens) — 0.3, 0.45, 0.625, 0.9, and 1.25 mg. Typical dose 0.3–0.625 mg daily. Still covered by most insurance plans but decreasingly prescribed.

Where oral is generally considered reasonable: no personal or family history of clots; no obesity; normal triglycerides; no migraine with aura; transdermal tried without symptom relief; or cost as the deciding factor (generic oral estradiol is pennies a day). Oral estrogen can also be slightly better at raising high-density lipoprotein (HDL) cholesterol, though the clinical importance of this is debated.

Where the research raises concern about oral estrogen: personal VTE history, strong family VTE history, known thrombophilia (Factor V Leiden, prothrombin mutation), migraine with aura, body mass index (BMI) over 30, high triglycerides, active gallbladder disease, or reliance on testosterone for libido/energy, which the SHBG rise lowers.

Starting Doses and Dose Adjustment

There is no single "right" dose — the aim described in guidance is the lowest dose that controls symptoms and protects bone. A typical dose-adjustment schedule for a newly menopausal woman starting transdermal estradiol:

Weeks 1–4: A common start is a 0.05 mg/day patch (twice-weekly or weekly) or equivalent gel (one 0.75 mg pump, or a 0.5–1.0 mg packet). For mild symptoms, or a first start over age 60, 0.025 mg is a common start.
Weeks 4–8: Reassessment. Hot flash frequency, night sweats, sleep quality, mood, vaginal dryness and brain fog are the things tracked; a simple daily 1–5 rating works. See the symptom tracker article for a template.
Weeks 8–12: With symptoms continuing, the usual step is up one increment — 0.05 to 0.075, or 0.075 to 0.1. With symptoms controlled but signs of too much estrogen (breast tenderness, bloating, headaches, spotting), the usual step is down.
Months 3–6: Most women find a stable dose. The 2022 NAMS position statement describes periodic reevaluation of the benefits and risks of continuing therapy.

Progesterone for women who still have a uterus. Unopposed estrogen thickens the uterine lining and raises endometrial cancer risk. Micronized progesterone 100 mg nightly continuous or 200 mg nightly for 12 days per month is the preferred partner — see the progesterone comparison.

Blood level testing is usually unnecessary. Estradiol serum levels on transdermal therapy do loosely correspond to symptom relief (typically 40–100 pg/mL on a 0.05–0.1 mg patch), but they fluctuate, so dosing is guided by symptoms rather than by the number. Testing is useful when symptoms are not responding at an apparently adequate dose — it can catch a poor absorber. See the hormone panel lab test page.

Switching Between Routes

Women switch routes for lots of reasons — insurance changes, skin reactions, new clot-risk information, travel convenience, or just curiosity about whether one will feel better than the other. Rough equivalencies prescribers use:

Oral estradiol 1 mg/day ≈ 0.05 mg/day patch ≈ 0.5–1.0 mg/day gel ≈ conjugated estrogens 0.625 mg/day.
Oral estradiol 2 mg/day ≈ 0.1 mg/day patch ≈ 1.5 mg/day gel ≈ conjugated estrogens 1.25 mg/day.

How the switch is usually done: the old route stops and the new route starts on the same day — no taper overlap. From patch to gel, the first gel dose goes on the morning the patch would have been changed. From oral to patch, the first patch goes on the morning after the last pill. A brief 1–2 week adjustment, with symptoms flaring slightly as steady-state shifts, is common. A recheck at 4–6 weeks, with dose adjustment if needed, is usual.

One note on the oral-to-transdermal switch: SHBG falls back toward baseline over 4–8 weeks, which raises free testosterone. Women who felt flat or low-libido on oral hormone replacement therapy may notice the switch within a month. Conversely, switching from transdermal to oral can bring an unexpected drop in free testosterone.

Absorption in Overweight and Obese Patients

Transdermal estradiol absorption varies with body fat and skin characteristics. A few real-world points:

Patches may underdeliver in women with higher body mass index — thicker subcutaneous fat under the adhesion site can slow movement of estradiol into capillary circulation. Some women with body mass index over 30 need 0.075 or 0.1 mg patches to get the symptom control a leaner woman gets from 0.05 mg.
Gel tends to be more consistent across body sizes because it is applied over a wider, thinner-skin area (arm or thigh) where vascularity is predictable.
Abdomen vs hip placement matters. In women with abdominal obesity, a lower abdominal patch may absorb less reliably than an upper hip or buttock placement. Moving the patch site to the hip for a cycle is one step used when relief is poor.
Oral estrogen and absorption problems in obesity. Obesity itself is a VTE risk factor, and oral estrogen adds a second clot risk on top of it; for this reason a higher transdermal dose or a switch to gel is the usual response to poor patch absorption.

Cost, Insurance, and Compounded Pellets

Costs vary dramatically by product. Ballpark U.S. retail with pharmacy discount programs (2025–2026 range):

Generic oral estradiol 1 mg — $5–$15 per month. Cheapest option by far.
Generic estradiol patch (twice weekly) — $15–$45 per month. Widely covered by insurance, often $0–$20 copay.
Brand-name estradiol patch — $80–$200 per month without insurance. Usually a $30–$60 copay with coverage.
Brand-name estradiol gels — $80–$250 per month retail. Insurance coverage varies; prior authorization is common.
Estradiol spray — similar to gels, often $150–$300 per month retail.
Conjugated estrogens — $150–$300 per month retail, though many plans cover it with a modest copay.

Where cost is the deciding factor, generic oral estradiol and generic patches are the lowest-cost options. Many compounding pharmacies offer "custom" transdermal creams at comparable prices to branded gels, but these are not U.S. Food and Drug Administration-approved and deliver unpredictable doses.

What the major societies say about compounded pellets. Estradiol and testosterone pellets — small drug implants inserted under the skin of the hip every 3–4 months — are heavily marketed by some clinics as "bioidentical hormone replacement." The estradiol in pellets is the same 17-beta-estradiol as in a patch, so "bioidentical" is technically true; that is not the problem. The problems are:

Pellets deliver supraphysiologic doses — often estradiol levels 2–5x higher than a premenopausal woman's own ovaries produced. These high levels are associated with more breast tenderness, spotting, and unknown long-term breast and endometrial safety.
A pellet cannot be stopped. A side effect lasts for months, until the pellet dissolves.
They are not U.S. Food and Drug Administration-approved for menopause. The Menopause Society, the Endocrine Society, and the American College of Obstetricians and Gynecologists all explicitly advise against them.
Cost is high — typically $300–$800 every 3–4 months, rarely covered by insurance, on top of the procedure fee.

Marketing of pellets as "safer" or "more natural" than a patch is not supported by the points above: the hormone is the same, the dose is higher, and it cannot be reversed. A generic estradiol patch plus micronized progesterone is the lower-cost FDA-approved combination.

What NAMS and Major Societies Say

The North American Menopause Society 2022 Hormone Therapy Position Statement is the current version of that statement (the 2023 NAMS position statement is a separate document on nonhormone therapy) and is the most widely cited guideline document in the English-speaking world. Its core points on route selection:

For women younger than 60 or within 10 years of menopause onset who have no contraindications, the benefit-risk ratio is favorable for treating bothersome hot flashes and night sweats (vasomotor symptoms) and for preventing bone loss.
Transdermal estradiol is preferred over oral in women with elevated VTE risk (obesity, personal or family clot history, thrombophilia, migraine with aura, active gallbladder disease, hypertriglyceridemia).
Transdermal is "reasonable first-line" even in women without these risk factors, reflecting the cleaner liver profile.
There is no required maximum duration of hormone replacement therapy. Decisions to continue past age 65 are individualized, not automatic.
Compounded hormone therapy — including pellets and custom creams — is not recommended over U.S. Food and Drug Administration-approved products for routine use.

The Endocrine Society, ACOG, and the International Menopause Society all publish parallel guidance that says essentially the same thing. The 2002 Women's Health Initiative scare — which used oral conjugated equine estrogens plus medroxyprogesterone acetate in women averaging 63 years old — is no longer considered representative of modern transdermal regimens in appropriately selected women. See the hormone replacement therapy risks article for a full discussion of what the WHI does and does not tell us in 2026.

Warning signs. The FDA patient information for the estradiol transdermal patch lists these warning signs: new breast lumps, unusual vaginal bleeding, changes in vision or speech, sudden new severe headaches, and severe pains in the chest or legs with or without shortness of breath, weakness and fatigue. A blood clot in a leg usually shows as swelling or pain in one leg; a clot that has reached the lungs as sudden shortness of breath or chest pain. A stroke shows as the BE FAST signs: sudden loss of Balance, blurred or lost vision (Eyes), a drooping Face, weakness in one Arm or leg, slurred or confused Speech — Time matters. Hospitals treat a suspected clot or stroke as an emergency.

Key Research Papers

Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007;115(7):840-5. The landmark paper showing oral HRT raises VTE risk roughly 4-fold while transdermal HRT does not. — doi:10.1161/CIRCULATIONAHA.106.642280; PubMed PMID: 17309934
The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022. Current U.S. guidance on HRT including explicit preference for transdermal in higher-risk patients. — doi:10.1097/GME.0000000000002028
Mohammed K, Abu Dabrh AM, Benkhadra K, et al. Oral vs Transdermal Estrogen Therapy and Vascular Events: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab. 2015;100(11):4012-20. Fifteen observational studies: oral estrogen associated with higher VTE risk than transdermal (risk ratio 1.63) and possibly stroke (risk ratio 1.24, a single case-control study); evidence warranting low confidence. — PubMed PMID: 26544651
The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause. 2023;30(6):573-590. — PubMed PMID: 37252752
PubMed search: transdermal estradiol, first-pass metabolism, and SHBG. Background on why oral estrogen doubles SHBG and lowers free testosterone. — Search PubMed
PubMed search: compounded bioidentical hormone pellets, safety review. Literature supporting why major societies advise against pellet therapy. — Search PubMed
PubMed search: conjugated equine estrogens vs 17-beta-estradiol comparative outcomes. — Search PubMed

Back to Table of Contents